Multiformic modulation of endotoxin effects by linomide

Clinical Immunology

Volumn 93, Issue 3, 1999, Pages 250-255

  Shalev, M ^a   Ko, A ^a   Gelderman, M P ^a   Fortin, E ^a   Reed, G ^a   Slavin, S ^b   Gery, I ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cytokines, production of; Endotoxin, effects of; Immunomodulation, by drugs; Inflammation, ocular; Linomide, effects of

Indexed keywords

ENDOTOXIN; IMMUNOMODULATING AGENT; ROQUINIMEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; UVEITIS;

EID: 0032765236     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4800     Document Type: Article

References (34)

1. Kalland T., Alm G., Stalhandshe T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 134:1985;3956-3961.
2. Stalhandshe T., Kalland T. Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat. Immunopharmacology. 11:1986;87-92.
3. Kalland T., Maksimova A., Stalhandshe T. Prophylaxis and treatment of experimental tumours with the immunomodulator LS 2616. Int. J. Immunopharmacol. 7:1985;390.
4. Karussis D. M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., Kalland T., Abramsky O. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. USA. 90:1993;6400-6404.
5. Diab A., Michael L., Wahren B., Deng G.-M., Björk J., Hedlund G., Zhu J. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J. Neuroimmunol. 85:1998;146-154.
6. Karpati T., Karussis D., Abramsky O., Mizrahi-Koll R., Arbell I., Ovadia H. Inhibition of experimental autoimmune neuritis by the immunomodulator linomide. Immunol. Lett. 63:1998;141-145.
7. Zhu J., Bai F., Hedlund G., Björk J., Bakhiet M., Van der Meide P. H., Link H. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clin. Exp. Immunol. 115:1999;56-63.
8. Shirkey B. L., Slavin S., Vistica B. P., Podgor M. J., Gery I. Immunomodulatory effects of linomide in animals immunized with immunopathogenic retinal antigens: Dissociation between different immune functions. Clin. Exp. Immunol. 108:1997;539-544.
9. Hutchings P., Hedlund G., Dawe K., Howlett S., Hooke A. Effect of the synthetic immunomodulator, linomide, on experimental models of thyroiditis. Immunology. 96:1999;340-347.
10. Karussis D. M., Lehmann D., Brenner T., Wirguin I., Mizrachi-Koll R., Sicssic C., Abramsky O. Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J. Neuroimmunol. 55:1994;187-193.
11. Gross D. J., Sidi H., Weiss L., Kalland T., Rosenmann E., Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by linomide, a novel immunomodulating drug. Diabetologia. 37:1994;1195-1201.
12. Bergh J. C., Totterman T. H., Termander B. C., Strandgarden K. A., Gunnarsson P. O., Nilsson B. I. The first clinical pilot study of roquinimex (linomide) in cancer patients with special focus on immunological effects. Cancer Invest. 15:1997;204-211.
13. Mackean M. J., Kerr D., Lesko M., Svedberg A., Hansson F., Jodrell D., Cassidy J. A feasibility study of roquinimex (linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma. Br. J. Cancer. 78:1998;1620-1623.
14. Andersen O., Lycke J., Tollesson P. O., Svenningsson A., Runmarker B., Linde A. S., Astrom M., Gjorstrup P., Ekholm S. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology. 47:1996;895-900.
15. Karussis D. M., Meiner Z., Lehmann D., Gomori J. M., Schwarz A., Linde A., Abramsky O. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology. 47:1996;341-346.
16. + cells. Clin. Immunol. Immunopathol. 85:1997;202-209.
17. Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 144:1990;4472-4476.
18. Gonzalo J. A., González-García A., Kalland T., Hedlund G., Martínez-A. C., Kroemer G. Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur. J. Immunol. 24:1994;48-52.
19. Bai X.-F., Shi F.-D., Zhu J., Xiao B.-G., Hedlund G., Link H. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J. Neuroimmunol. 76:1997;177-184.
20. Arad G., Katzenellenbogen M., Levy R., Slavin S., Kaempfer R. Linomide, an immunomodulator that inhibits Th1 cytokine gene expression. Int. Immunol. 8:1996;1603-1607.
21. Tian W. Z., Navikas V., Matusevicius D., Soderstrom M., Fredrikson S., Hedlund G., Link H. Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. Acta Neurol. Scand. 98:1998;94-101.
22. Erälinna J.-P., Röytta M., Hukkanen V., Zinhu D., Salmi A. A., Salonen R. Selective downregulation of Th1 response by linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice. J. Neuroimmunol. 88:1998;165-176.
23. Lehmann D., Karussis D. M., Fluresco D., Mizrachi-Koll R., Ovadia H., Shezen E., Kalland T., Abramsky O. Immunomodulation of autoimmunity by linomide: Inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 74:1997;102-110.
24. Rosenbaum J. T., McDevitt H. O., Guss R. B., Egbert P. R. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 286:1980;611-613.
25. Kasner L., Chan C.-C., Whitcup S. M., Gery I. The paradoxical effect of tumor necrosis factor alpha (TNF-α) in endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 34:1993;2911-2917.
26. de Vos A. F., Klaren V. N., Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest. Ophthalmol. Vis. Sci. 35:1994;3873-3883.
27. Planck S. R., Huang X. N., Robertson J. E., Rosenbaum J. T. Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment. Invest. Ophthalmol. Vis. Sci. 35:1994;924-930.
28. Yoshida M., Yoshimura N., Hangai M., Tanihara H., Honda Y. Interleukin-1 alpha, interleukin-1 beta, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 35:1994;1107-1113.
29. Morrison D. C., Danner R. L., Dinarello C. A., Munford R. S., Natanson C., Pollack M., Spitzer J. A., Ulevitch R. J., Vogel S. N., McSweegan E. Bacterial endotoxins and pathogenesis of Gram-negative infections: Current status and future directions. J. Endotoxin Res. 1:1994;71-83.
30. Lefkowitz D. L., Lefkowitz S. S., Wei R. Q., Everse J. Activation of macrophages with oxidative enzymes. Methods Enzymol. 132:1986;537-548.
31. de Vos A. F., van Haren M. A., Verhagen C., Hoekzema R., Kijlstra A. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp. Eye Res. 61:1995;667-675.
32. Gonzalo J. A., González-García A., Kalland T., Hedlund G., Martínez-A. C., Kroemer G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur. J. Immunol. 23:1993;2372-2374.
33. Wang B., Ishihara M., Egashira Y., Ohta T., Sanada H. Effects of various kinds of dietary amino acids on the hepatotoxic action of d-galactosamine in rats. Biosci. Biotechnol. Biochem. 63:1999;319-322.
34. Zhang G.-X., Yu L.-Y., Shi F.-D., Xiao B.-G., Björk J., Hedlund G., Link H. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis. J. Neuroimmunol. 73:1997;175-182.